Eversept Partners’s MacroGenics MGNX Stock Holding History

Eversept Partners’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-91,998	Closed	-$535K	–	76
2020 Q1	$535K	Sell	91,998 -25,000	-21%	-$227K	0.13%	54
2019 Q4	$1.27M	Sell	116,998 -37,826	-24%	-$374K	0.22%	60
2019 Q3	$1.98M	Sell	154,824 -35,799	-19%	-$516K	0.61%	35
2019 Q2	$3.23M	Buy	+190,623	New	+$3.27M	0.91%	26

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Eversept Partners's MGNX Position: Q2 2020 in Review

Eversept Partners sold out of MacroGenics (MGNX) in Q2 2020, closing a stake of 91,998 shares — an estimated $535K sold.

Eversept Partners first reported a position in MGNX in Q2 2019 and held it in 4 quarters. The position peaked at $3.23M in Q2 2019. 137 funds tracked by Wall St. Rank hold MGNX as of Q2 2020.

Eversept Partners reported no remaining MacroGenics position as of Q2 2020 after selling out during the quarter.
Eversept Partners sold 91,998 MacroGenics shares in Q2 2020, an estimated $535K.
Eversept Partners first reported a position in MacroGenics in Q2 2019 and held it in 4 quarters.
Eversept Partners's MacroGenics position peaked at $3.23M in Q2 2019.
137 funds tracked by Wall St. Rank held MacroGenics as of Q2 2020.

Based on Eversept Partners's 13F filing for Q2 2020, filed 13 Aug 2020.